Actavis Establishes New R&D Labs in Florida
Posted on: Tuesday, 4 November 2008, 12:00 CST
Actavis South Atlantic, a US division of the generic pharmaceutical company Actavis, has opened new analytical and R&D laboratories to expand the company's R&D efforts for controlled release and other technically difficult generic pharmaceutical products.
The new analytical labs have been expanded by 3,000 square feet and the new R&D labs have been expanded by 1,500 square feet. As part of the Sunrise, Florida expansion, appropriate office space was also added to support both of the lab expansions.
Recently launched Actavis South Atlantic products in the US include Bupropion XL and SR, the generic equivalents of Glaxosmithline's Wellbutrin XL and SR as well as Nifedipine ER, the generic equivalent of Bayer's Adalat CC.
Doug Boothe, CEO of Actavis US, said: "Actavis in the US is focused on our vision and commitment to be on the cutting edge of new technology. The expansion of our South Atlantic R&D facility ensures that we remain well-positioned to develop and manufacture XL and continuous release drugs."
Source: Datamonitor
Related Articles
- Seesaw Link Between North And South Atlantic Climates
- James R. Thomas Appointed President of South Atlantic Division
- J.D. Power and Associates Study Ranks Kaiser Permanente Highest in Member Satisfaction in South Atlantic Region
- Oceana Report Describes Threat to South Atlantic and Gulf Ocean Habitat By Deep-Sea Trawls
- Cousins Signs American Cancer Society to 274,000-Square-Foot Lease in Downtown Atlanta; Move Brings ACS' International and South Atlantic HQs to Inforum; Building Now 98 Percent Leased
- ILA's South Atlantic and Gulf Coast District to Meet September 12 & 13 in Houston to Organize Relief Effort for Devastated Gulf Port Areas
- Focus On Our Magnetic Planet
- Scientists Claim to Discover New Fish Species
- Scientists Claim to Discover New Fish
 |
 |
User Comments (0)
RSS Feeds